Induction of angiogenesis by expression of soluble type II transforming growth factor-beta receptor in mouse hepatoma - PubMed (original) (raw)
. 2001 Oct 19;276(42):38781-6.
doi: 10.1074/jbc.M104944200. Epub 2001 Jul 16.
Affiliations
- PMID: 11457844
- DOI: 10.1074/jbc.M104944200
Free article
Induction of angiogenesis by expression of soluble type II transforming growth factor-beta receptor in mouse hepatoma
K Y Kim et al. J Biol Chem. 2001.
Free article
Abstract
The biological effect of transforming growth factor-beta (TGF-beta) is cell type-specific and complex. The precise role of TGF-beta is not clear in vivo. To elucidate the regulation mechanism of endogenous TGF-beta on hepatoma progression, we modified the MH129F mouse hepatoma cell with a retroviral vector encoding the extracellular region of type II TGF-beta receptor (TRII). Soluble TRII (TRIIs) blocked TGF-beta binding to TRII on the membrane of hepatoma cells. Growth of MH129F cells was inhibited by TGF-beta1 treatment; however, soluble TRII-overexpressing cells (MH129F/TRIIs) did not show any change in proliferation after TGF-beta1 treatment. MH129F/TRIIs cells also increased vascular endothelial growth factor (VEGF) expression, endothelial cell migration, and tube formation. Implantation of MH129F/TRIIs cells into C3H/He mice showed the significantly enhanced tumor formation. According to Western blot and protein kinase C assay, the expression of VEGF, KDR/flk-1 receptor, and endothelial nitric-oxide synthase was enhanced, and the phosphorylation activity of protein kinase C was increased up to 3.7-fold in MH129F/TRIIs tumors. Finally, a PECAM-1-stained intratumoral vessel was shown to be 4.2-fold higher in the MH129F/TRIIs tumor. These results indicate that VEGF expression is up-regulated by a blockade of endogenous TGF-beta signaling in TGF-beta-sensitive hepatoma cells and then stimulates angiogenesis and tumorigenicity. Therefore, we suggest that endogenous TGF-beta is a major regulator of the VEGF/flk-1-mediated angiogenesis pathway in hepatoma progression.
Similar articles
- Loss of endogenous TGF-beta effect induces mouse hepatoma malignancy by correlation with cyclooxygenase-2 and VEGF.
Kim KY, Lee JW, Ahn BW, Ryu PD, Nam MJ. Kim KY, et al. Hepatol Res. 2003 Aug;26(4):302-310. doi: 10.1016/s1386-6346(03)00155-4. Hepatol Res. 2003. PMID: 12963430 - Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway.
Shen BQ, Lee DY, Zioncheck TF. Shen BQ, et al. J Biol Chem. 1999 Nov 12;274(46):33057-63. doi: 10.1074/jbc.274.46.33057. J Biol Chem. 1999. PMID: 10551875 - Transforming growth factor-beta and Ras regulate the VEGF/VEGF-receptor system during tumor angiogenesis.
Breier G, Blum S, Peli J, Groot M, Wild C, Risau W, Reichmann E. Breier G, et al. Int J Cancer. 2002 Jan 10;97(2):142-8. doi: 10.1002/ijc.1599. Int J Cancer. 2002. PMID: 11774256 - Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine.
Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM, Dvorak HF. Brown LF, et al. EXS. 1997;79:233-69. doi: 10.1007/978-3-0348-9006-9_10. EXS. 1997. PMID: 9002222 Review. - Signaling by members of the TGF-beta family in vascular morphogenesis and disease.
Pardali E, Goumans MJ, ten Dijke P. Pardali E, et al. Trends Cell Biol. 2010 Sep;20(9):556-67. doi: 10.1016/j.tcb.2010.06.006. Epub 2010 Jul 23. Trends Cell Biol. 2010. PMID: 20656490 Review.
Cited by
- Tumor angiogenesis: insights and innovations.
Nussenbaum F, Herman IM. Nussenbaum F, et al. J Oncol. 2010;2010:132641. doi: 10.1155/2010/132641. Epub 2010 Apr 26. J Oncol. 2010. PMID: 20445741 Free PMC article. - Angiogenesis and organ transplantation.
Rajnoch J, Viklický O. Rajnoch J, et al. Folia Microbiol (Praha). 2004;49(5):499-505. doi: 10.1007/BF02931524. Folia Microbiol (Praha). 2004. PMID: 15702536 Review. - Biological evaluation of transdichloridoplatinum(II) complexes with 3- and 4-acetylpyridine in comparison to cisplatin.
Filipovic L, Arandelovic S, Gligorijevic N, Krivokuca A, Jankovic R, Srdic-Rajic T, Rakic G, Tesic Z, Radulovic S. Filipovic L, et al. Radiol Oncol. 2013 Oct 8;47(4):346-57. doi: 10.2478/raon-2013-0050. eCollection 2013. Radiol Oncol. 2013. PMID: 24294179 Free PMC article. - TGF-beta antagonists: why suppress a tumor suppressor?
Akhurst RJ. Akhurst RJ. J Clin Invest. 2002 Jun;109(12):1533-6. doi: 10.1172/JCI15970. J Clin Invest. 2002. PMID: 12070299 Free PMC article. Review. No abstract available. - Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury.
Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, Yasui K, Takeuchi M, Makita Z, Takasawa S, Okamoto H, Watanabe T, Yamamoto H. Yonekura H, et al. Biochem J. 2003 Mar 15;370(Pt 3):1097-109. doi: 10.1042/BJ20021371. Biochem J. 2003. PMID: 12495433 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources